The DOI matches its Crossref record.
Cytokine Receptors and Signaling in Hepatic Stellate Cells
Abstract
Following acute or chronic liver tissue damage, hepatic stellate cells (HSCs) undergo a process of activation toward a phenotype characterized by increased proliferation, motility, contractility, and synthesis of extracellular matrix components. Activation of HSCs is regulated by several soluble factors, including growth factors, cytokines, chemokines, and products of oxidative stress, as well as by extensive changes in the composition and organization of the ECM. Different groups of soluble factors may be classified according to their prevalent biological effect: (a) factors promoting HSC proliferation and/or migration (i.e., platelet-derived growth factor, basic fibroblast growth factor, insulin-like growth factor-1); (b) factors promoting fibrillar ECM accumulation, particularly transforming growth factor-beta1; (c) factors with a prevalent contractile effect on HSCs, such as endothelin-1, thrombin, angiotensin-II and vasopressin, although all these agents also may promote HSC proliferation; (d) proinflammatory cytokines and chemokines; and (e) cytokines with a prominent antiinflammatory/antifibrogenic activity, such as interleukin-10 and interferon-gamma. Additional important issues are represented by the relationship between cytokine and integrin signaling, and by the effects of oxidative stress-related molecules on cytokine signaling. In the past decade the major intracellular signaling pathways elicited by these factors in HSCs have been greatly elucidated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Regulation of PDGF and its receptors in fibrotic diseases
Bonner, J. C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.006 · Cited by 768
Fernández, M., Semela, D., Bruix, J., Colle, I., Pinzani, M., & Bosch, J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.011 · Cited by 600
Self-citationEvolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Apoptosis: The nexus of liver injury and fibrosis
Canbay, A., Friedman, S., & Gores, G. J. (2004) · Hepatology · doi:10.1002/hep.20051 · Cited by 527
Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications
Friedman, S. L. (2004) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0055 · Cited by 498
CCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431
Activation of hepatic stellate cells - a key issue in liver fibrosis
Reeves, H. (2002) · Frontiers in Bioscience · doi:10.2741/reeves · Cited by 423
Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic
Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., & Gores, G. J. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000069036.63405.5c · Cited by 417
The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis
Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005) · Apoptosis · doi:10.1007/s10495-005-1055-4 · Cited by 419
The Hippo pathway effector YAP controls mouse hepatic stellate cell activation
Mannaerts, I., Leite, S. B., Verhulst, S., Claerhout, S., Eysackers, N., Thoen, L. F. R., Hoorens, A., Reynaert, H., Halder, G., & van Grunsven, L. A. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.011 · Cited by 410
Redox mechanisms in hepatic chronic wound healing and fibrogenesis
Novo, E., & Parola, M. (2008) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-1-5 · Cited by 406
Friedman, S. L. (2008) · Toxicology · doi:10.1016/j.tox.2008.06.013 · Cited by 350
Liver fibrosis: from the bench to clinical targets
Pinzani, M., & Rombouts, K. (2004) · Digestive and Liver Disease · doi:10.1016/j.dld.2004.01.003 · Cited by 336
Self-citationHepatic fibrosis: molecular mechanisms and drug targets
Lotersztajn, S., Julien, B., Teixeira-Clerc, F., Grenard, P., & Mallat, A. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095906 · Cited by 325
Fas enhances fibrogenesis in the bile duct ligated mouse: A link between apoptosis and fibrosis
Canbay, A., Higuchi, H., Bronk, S. F., Taniai, M., Sebo, T. J., & Gores, G. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35953 · Cited by 305
Adipogenic Transcriptional Regulation of Hepatic Stellate Cells
She, H., Xiong, S., Hazra, S., & Tsukamoto, H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410078200 · Cited by 299
Zhan, S.-S., Jiang, J. X., Wu, J., Halsted, C., Friedman, S. L., Zern, M. A., & Torok, N. J. (2006) · Hepatology · doi:10.1002/hep.21093 · Cited by 284
Interleukin-1 participates in the progression from liver injury to fibrosis
Gieling, R. G., Wallace, K., & Han, Y.-P. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90564.2008 · Cited by 281
Puche, J. E., Lee, Y. A., Jiao, J., Aloman, C., Fiel, M. I., Muñoz, U., Kraus, T., Lee, T., Yee, H. F., & Friedman, S. L. (2013) · Hepatology · doi:10.1002/hep.26053 · Cited by 136
Hepatic Fibrosis, Stellate Cells, and Portal Hypertension
Rockey, D. C. (2006) · Clinics in Liver Disease · doi:10.1016/j.cld.2006.08.017 · Cited by 112
Hillebrandt, S., Goos, C., Matern, S., & Lammert, F. (2002) · Gastroenterology · doi:10.1053/gast.2002.37069 · Cited by 104
Lhx2 –/– mice develop liver fibrosis
Wandzioch, E., Kolterud, Å., Jacobsson, M., Friedman, S. L., & Carlsson, L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404678101 · Cited by 95
CUG-binding protein 1 regulates HSC activation and liver fibrogenesis
Wu, X., Wu, X., Ma, Y., Shao, F., Tan, Y., Tan, T., Gu, L., Zhou, Y., Sun, B., Sun, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms13498 · Cited by 88
Sumpter, T. L., Dangi, A., Matta, B. M., Huang, C., Stolz, D. B., Vodovotz, Y., Thomson, A. W., & Gandhi, C. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200819 · Cited by 72
Antifibrotic Agents for Liver Disease
Albanis, E., & Friedman, S. L. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2005.01143.x · Cited by 68
Ye, Y., & Dan, Z. (2010) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-010-0648-5 · Cited by 28
Knockdown of miR-23, miR-27, and miR-24 alters fetal liver development and blocks fibrosis in mice
Rogler, C. E., Matarlo, J. S., Kosmyna, B., Fulop, D., & Rogler, L. E. (2017) · Gene Expression · doi:10.3727/105221616x693891 · Cited by 23
Human Liver-Derived Extracellular Matrix for the Culture of Distinct Human Primary Liver Cells
Alevra Sarika, N., Payen, V. L., Fléron, M., Ravau, J., Brusa, D., Najimi, M., De Pauw, E., Eppe, G., Mazzucchelli, G., Sokal, E. M., et al. (2020) · Cells · doi:10.3390/cells9061357 · Cited by 18
Metadata
- Authors
- Pinzani, M., & Marra, F.
- Venue
- Seminars in Liver Disease
- Publisher
- Georg Thieme Verlag KG
- Published
- 2001
- Volume
- 21
- Issue
- 03
- Pages
- 397-416
- ISSN
- 0272-8087 (ISSN-L)
- 1098-8971
- OpenAlex
- W1998931253
- Cited by
- 431
- References
- 0
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.